Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.

Bassetti M, Aversa F, Ballerini F, Benedetti F, Busca A, Cascavilla N, Concia E, Tendas A, Di Raimondo F, Mazza P, Nosari AM, Rossi G.

Clin Drug Investig. 2011 Nov 1;31(11):745-58. doi: 10.2165/11593760-000000000-00000. Review.

PMID:
21888451
2.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
3.

The current role of amphotericin B lipid complex in managing systemic fungal infections.

Chu P, Sadullah S.

Curr Med Res Opin. 2009 Dec;25(12):3011-20. doi: 10.1185/03007990903379077. Review.

PMID:
19849324
4.

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

Tiphine M, Letscher-Bru V, Herbrecht R.

Transpl Infect Dis. 1999 Dec;1(4):273-83. Review.

PMID:
11428998
5.

Amphotericin B lipid complex for the treatment of invasive fungal infections.

Linden PK.

Expert Opin Pharmacother. 2003 Nov;4(11):2099-110. Review.

PMID:
14596663
6.

Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.

Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP.

Pharmacoeconomics. 2004;22(5):301-10.

PMID:
15061680
7.
8.
9.

Amphotericin B lipid complex.

Rapp RP, Gubbins PO, Evans ME.

Ann Pharmacother. 1997 Oct;31(10):1174-86. Review.

PMID:
9337444
11.

Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.

Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL.

Appl Health Econ Health Policy. 2014 Feb;12(1):85-93. doi: 10.1007/s40258-013-0072-7.

PMID:
24385260
13.

Amphotericin B formulations: a comparative review of efficacy and toxicity.

Hamill RJ.

Drugs. 2013 Jun;73(9):919-34. doi: 10.1007/s40265-013-0069-4. Review.

PMID:
23729001
14.
15.

Lipid formulations of amphotericin B.

Dix SP, Andriole VT.

Curr Clin Top Infect Dis. 2000;20:1-23. Review.

PMID:
10943516
16.

Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?

Ellis M.

Transpl Infect Dis. 2000 Jun;2(2):51-61. Review.

PMID:
11429013
17.
18.

Amphotericin B lipid complex in pediatric patients with invasive fungal infections.

Walsh TJ, Seibel NL, Arndt C, Harris RE, Dinubile MJ, Reboli A, Hiemenz J, Chanock SJ.

Pediatr Infect Dis J. 1999 Aug;18(8):702-8.

PMID:
10462340
19.

Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.

Borro JM, Solé A, de la Torre M, Pastor A, Fernandez R, Saura A, Delgado M, Monte E, Gonzalez D.

Transplant Proc. 2008 Nov;40(9):3090-3. doi: 10.1016/j.transproceed.2008.09.020.

PMID:
19010204
20.

Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.

Bellmann R, Cleary JD, Sterba J.

Clin Adv Hematol Oncol. 2009 Apr;7(4):1-8. Review.

PMID:
19537331
Items per page

Supplemental Content

Support Center